Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects

被引:127
作者
Romero, Fabiola [1 ]
Nicolau, Joana [1 ]
Flores, Lilliam [1 ,2 ,3 ]
Casamitjana, Roser [1 ,2 ,3 ]
Ibarzabal, Ainitze [1 ]
Lacy, Antonio [1 ,3 ]
Vidal, Josep [1 ,2 ,3 ]
机构
[1] Hosp Clin Univ, Dept Endocrinol & Diabet, Obes Unit, Barcelona 08036, Spain
[2] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
[3] Inst Invest Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2012年 / 26卷 / 08期
关键词
Gastric bypass; GIP; GLP-1; GLP-2; Glucagon; Sleeve gastrectomy; GLUCAGON-LIKE PEPTIDE-1; BETA-CELL FUNCTION; WEIGHT-LOSS; BARIATRIC SURGERY; INCRETIN LEVELS; GLUCOSE; SECRETION; MELLITUS; SUPPRESSION; TRIAL;
D O I
10.1007/s00464-012-2166-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGBP) are associated with similar type 2 diabetes mellitus (T2DM) resolution rates for morbidly obese subjects. However, the mechanisms underlying the resolution of T2DM after SG have not been clarified to date. This study aimed to compare the early changes in gastrointestinal hormones involved in insulin and glucagon secretion in morbidly obese T2DM subjects undergoing SG or RYGBP. This prospective study investigated 12 subjects with T2DM who had undergone SG (n = 6) or RYGBP (n = 6). Five body mass index (BMI)-matched obese non-diabetic subjects and five BMI-matched obese diabetic subjects served as control subjects. Glucose, insulin, glucagon, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and GLP-2 were determined after a standardized mixed liquid meal before surgery and 6 weeks afterward. After 6 weeks, five of the six subjects in each surgical group presented with T2DM remission, although the area under the curve (AUC)(0-120) of glucose was greater than that of the non-diabetic control subjects (P < 0.01). Postsurgically, the indices of insulin and glucagon secretion were comparable between the two surgical groups. The AUC(0-120) of GLP-1 (P < 0.05) and GLP-2 (P < 0.05) was significantly and comparably enlarged after SG and RYGB. The postsurgical GIP response was significantly associated with the glucagon response throughout the meal test (rho = 0.747; P < 0.01). The data show that in a cohort of morbidly obese T2DM subjects, SG and RYGBP are associated with an early improvement in glucose tolerance, similar changes in insulin and glucagon secretion, and a similar GLP-1, GIP, and GLP-2 response to a standardized mixed liquid meal.
引用
收藏
页码:2231 / 2239
页数:9
相关论文
共 50 条
[41]   Roux-en-Y gastric bypass vs sleeve gastrectomy for obese patients with type 2 diabetes: a randomised trial [J].
Andrei Keidar ;
Karen J. Hershkop ;
Limor Marko ;
Chaya Schweiger ;
Lior Hecht ;
Noam Bartov ;
Assaf Kedar ;
Ram Weiss .
Diabetologia, 2013, 56 :1914-1918
[42]   Roux-en-Y gastric bypass versus sleeve gastrectomy: risks and benefits [J].
Ettleson, Matthew D. ;
Lager, Corey J. ;
Kraftson, Andrew T. ;
Sfandiari, Nazanene H. E. ;
Oral, Elif A. .
MINERVA CHIRURGICA, 2017, 72 (06) :505-519
[43]   Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? [J].
Torquati, A ;
Lutfi, R ;
Abumrad, N ;
Richards, WO .
JOURNAL OF GASTROINTESTINAL SURGERY, 2005, 9 (08) :1112-1116
[44]   Changes in Gastrointestinal Hormones and Leptin after Roux-en-Y Gastric Bypass Procedure: A Review [J].
Beckman, Lauren M. ;
Beckman, Tiffany R. ;
Earthman, Carrie P. .
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2010, 110 (04) :571-584
[45]   Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients [J].
Blanchard, C. ;
Ledoux, S. ;
Verhaegen, A. ;
Wargny, M. ;
Letessier, E. ;
Stepanian, A. ;
Huten, N. ;
Jacobi, D. ;
Krempf, M. ;
Le Bras, M. ;
Guillouche, M. Perrocheau ;
Arnaud, L. ;
Pichelin, M. ;
Van Gaal, L. ;
Cariou, B. ;
Le May, C. .
DIABETES & METABOLISM, 2020, 46 (06) :480-487
[46]   Is roux-en-y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? [J].
Alfonso Torquati ;
Rami Lutfi ;
Naji Abumrad ;
William O. Richards .
Journal of Gastrointestinal Surgery, 2005, 9 :1112-1118
[47]   Metabolic Surgery Comparing Sleeve Gastrectomy with Jejunal Bypass and Roux-en-Y Gastric Bypass in Type 2 Diabetic Patients After 3 Years [J].
Matías Sepúlveda ;
Munir Alamo ;
Yudith Preiss ;
Juan P. Valderas .
Obesity Surgery, 2018, 28 :3466-3473
[48]   Comparative Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Glucose Homeostasis and Incretin Hormones in Obese Type 2 Diabetic Patients: A One-Year Prospective Study [J].
Nosso, G. ;
Griffo, E. ;
Cotugno, M. ;
Saldalamacchia, G. ;
Lupoli, R. ;
Pacini, G. ;
Riccardi, G. ;
Angrisani, L. ;
Capaldo, B. .
HORMONE AND METABOLIC RESEARCH, 2016, 48 (05) :312-317
[49]   Evaluation of Metabolic Syndrome in morbidly Obese Patients Submitted to Laparoscopic Bariatric Surgery: Comparison of the Results between Roux-En-Y Gastric Bypass and Sleeve Gastrectomy [J].
Rodrigo Koprovski Menguer ;
Antônio Carlos Weston ;
Helena Schmid .
Obesity Surgery, 2017, 27 :1719-1723
[50]   Laparoscopic Conversion of a Sleeve Gastrectomy to the Roux-en-Y Gastric Bypass [J].
Ben Amor, Imed ;
Debs, Tarek ;
Martini, Francesco ;
Elias, Bachir ;
Kassir, Radwan ;
Gugenheim, Jean .
OBESITY SURGERY, 2015, 25 (08) :1556-1557